SCHEMBL4649325

SCHEMBL4649325

O=C(Cl)c1ccc2sc(I)cc2c1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 7/20 0.40
▸ DYRK1B Q9Y463 7/20 0.40
▸ CLK1 P49759 6/20 0.40
▸ HDAC1 Q13547 4/20 0.37
▸ TBXAS1 P24557 1/20 0.37
▸ HDAC6 Q9UBN7 7/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC2 Q92769 2/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B1 P14061 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19554202 0.80 DYRK1A (0.41) DYRK1ADYRK1BCLK1HDAC1HDAC6
SCHEMBL19029299 0.77 HDAC1 (0.50) HDAC1HDAC6NPC1RAB9ASMN1; SMN2
SCHEMBL727139 0.73 CES2 (0.52) DYRK1ADYRK1BCLK1NPC1RAB9A
SCHEMBL29375279 0.73 CES2 (0.52) DYRK1ADYRK1BCLK1NPC1RAB9A
SCHEMBL11809774 0.72 CYP1A2 (0.47) DYRK1ADYRK1BCLK1HDAC1TBXAS1
SCHEMBL1021640 0.72 CTNNB1 (0.57) DYRK1AHDAC8NPC1RAB9ASMN1; SMN2
SCHEMBL9390563 0.71 CES2 (0.42) DYRK1ADYRK1BCLK1NPC1RAB9A
SCHEMBL1681902 0.71 CES2 (0.50) SMN1; SMN2
SCHEMBL18003152 0.70 CYP2A6 (0.39) HDAC6NPC1RAB9ASMN1; SMN2
SCHEMBL8775402 0.69 LCK (0.48) DYRK1ADYRK1BCLK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963255-A1 SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS UNIVERSITEIT GENT (BE) 2008-09-03 — — EP disclosed
WO-2007071452-A1 SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS UNIVERSITEIT GENT (BE) 2007-06-28 — — WO disclosed
Send feedback